Business growth

Pfizer has begun the final phase of clinical trials of 3 vaccines. Two trials began for a 20valent pneumococcal vaccine and one trial each for a 5valent meningococcal vaccine for adolescents and a vaccine against respiratory syncytial virus for pregnant women. In the event of positive results for all candidates, the company's portfolio will be supplemented with three drugs that will help cure deadly infectious diseases.